Bactigard is informed that European Patent Office (EPO) intends to issue a European patent for of Bactigard infection prevention technology. The new patent, which is the third generation, will provide broad worldwide protection to Bactigard technologies by 2039
– We are very pleased that the EPO has confirmed that the new generation of patents will be granted. This will further strengthen and expand global protection for multilaterals Bactigard technology and make it even more attractive to existing and new licensing partners, he says Anders JöranssonCEO.
More than 30 years of Bactigard a unique technology based on a thin noble metal alloy coating has been developed and applied to medical devices for both short-term and long-term use. In 1994, urinary catheters with of Bactigard the coating was approved by the FDA in USA and have since become market leaders in USA and Japan through our partnership with BD (Becton, Dickinson and Company). in 2019 Bactigard initiates global partnership with Zimmer Biomet and in 2021 orthopedic trauma implants, ZNN Bactiguard, were launched. in February 2022on Zimmer Biomet the partnership was expanded to cover most of their product portfolio. Our latest development partnership is with Dentsply Sirona in the field of dentistry.
The Bactigard the technology can be used in most areas where there is a need for infection prevention and tissue-friendly properties and is based on a valuable recipe, a well-kept trade secret. It is also patent protected. The present patent, second generation, is effective in USA by 2027 and by 2029 in other countries. The application for the third generation of patents was filed in 2019 and the EPO has already confirmed that it intends to issue a European patent valid until 2039.
For more information, please contact:
Anders JöranssonCEO, +46 8 440 58 80
Bactigard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and deliver infection prevention solutions that reduce the risk of infection and the use of antibiotics. In this way, we save significant costs for healthcare and society as a whole.
The Bactigard the technology is based on a thin coating of a noble metal alloy that prevents bacterial adhesion and biofilm formation on medical devices. Bactigard offers the technology through licensing agreements and our portfolio of BIP (Bactiguard Infection Protection) products. Urinary catheters with Bactigard technologies are leading the market in USA and Japan through our licensing partner BD, and in 2021 the orthopedic trauma implants, ZNN Bactiguard, were launched by Zimmer Biomet. BactigardThe product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills microbes while being biocompatible and tissue-friendly.
Bactigard is in a phase of strong expansion of the markets in Europe, China, Indiaon Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapeutic areas. Bactigard has about 210 employees worldwide. The headquarters and one of the three production plants are located in Stockholmthe other two in Malaysia. Bactigard is listed on Nasdaq Stockholm.
Read more about Bactigard www.bactiguard.com
(c) 2022 Cision. All rights reserved., source Press releases – English